NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA and insurer Anthem have issued positive coverage decisions for Myriad Genetics' breast cancer recurrence test EndoPredict, the company announced.

“We now have nearly full coverage for EndoPredict testing in the United States which was accomplished in an unprecedented time of less than six months after our launch,” Myriad CEO Mark Capone said in a statement. Once these coverage decisions are fully implemented, 90 percent of breast cancer patients will have coverage for EndoPredict, Myriad estimated.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.